Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer

Baomin Chen1,*, Donghua Zheng2,*, Weiguang Yu3, Cuiping Huang3, Junxing Ye4, Guowei Han3 and Jintao Zhuang5

Abstract

Objective: To assess the efficacy and safety of cetuximab (CE) versus bevacizumab (BE) maintenance treatment after prior 8-cycle modified 5-fluorouracil, folinate, oxaliplatin, and irinotecan (FOLFOXIRI) plus CE induction therapy in treatment-naive KRAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC).

*These authors contributed equally to this work

Corresponding authors:
Junxing Ye, Department of Orthopaedics, The Third People’s Hospital of Wuxi, Jiangsu Province; The Affiliated Hospital of Jiangnan University, No. 585, Xingyuan North Road, Liangxi District, Wuxi, Jiangsu 214000, China.
Email: yejunxing0514@163.com
Guowei Han, Department of Orthopaedics, The First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou 510080, China.
Email: hanson9797@163.com
Jintao Zhuang, Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou 510080, China.
Email: brianzg86@163.com
Methods: From 2012 to 2017, prospectively maintained databases were reviewed to assess Asian postmenopausal women with treatment-naive KRAS and BRAF wt mCRC who underwent modified FOLFOXIRI plus CE induction therapy, followed by CE or BE maintenance until disease progression or death. Co-primary clinical endpoints were progression-free survival (PFS) and overall survival (OS).

Results: A total of 222 women were included (CE n = 110 and BE n = 112). At a median follow-up of 27.0 months (interquartile range, 6.5–38.6 months), median PFS was 21.9 months (95% confidence interval [CI] 16.4–24.4) and 17.7 months (95% CI 11.3–19.0) for CE and BE groups, respectively (hazard ratio [HR] 0.31, 95% CI 0.15–0.46); median OS was 26.0 months (95% CI 23.4–28.7) and 22.7 months (95% CI 21.2–24.3) for CE and BE groups, respectively (HR 0.22, 95% CI 0.11–0.37).

Conclusions: CE maintenance treatment is more poorly tolerated but has a slightly more modest survival benefit compared with BE maintenance treatment in mCRC.

Keywords
Cetuximab, bevacizumab, colorectal cancer, progression-free survival, overall survival, postmenopausal women

Date received: 14 February 2020; accepted: 5 May 2020

Introduction
Evidence-based statistics demonstrated that 43% of metastatic colorectal cancers (mCRC) are KRAS and BRAF wild-type (wt), and the treatment of such patients remains a challenge. Their median survival time is highly variable, ranging from 6 to 18 months, with a large range within each study subgroup. Furthermore, optimal treatment strategies are highly controversial, aiming to balance a favorable effect on progression-free survival (PFS) and overall survival (OS) versus adverse events (AEs) in these patients.

Combination treatment schedules with a modified 5-fluorouracil, folinate, oxaliplatin, and irinotecan (FOLFOXIRI) regimen plus a molecularly targeted drug (cetuximab [CE] or bevacizumab [BE]) in the first-line setting have been acknowledged as the standard processing scheme on the basis of published clinical efficacy and safety profiles. Previous investigators have carried out prospective Phase 1 and 2 trials to establish the safety and efficacy of modified FOLFOXIRI plus CE in the setting of KRAS and BRAF wt mCRC. The most recent randomized phase 2 clinical trial demonstrated that excluding patients with other RAS-mutated tumors from the KRAS and BRAF wt population may improve the benefit associated with adding CE to modified FOLFOXIRI, which is considered the best approach due to its potential to maximize the survival benefit as initial management in patients with KRAS and BRAF wt mCRC. Nevertheless, no data regarding postmenopausal women or a comparison of CE and BE are available. Furthermore, no optimal schedule has yet been confirmed for postmenopausal women whose tumors harbor KRAS and BRAF wt mutations and whose disease progresses following a first-line combination of modified FOLFOXIRI. Additionally, PFS and OS with this schedule have never been assessed in Asian postmenopausal women.

We therefore conducted a retrospective review of Asian postmenopausal women...
with treatment-naive KRAS and BRAF wt mCRC. To our knowledge, this is the first analysis that directly compares the efficacy and safety of CE against BE as maintenance treatment following prior 8-cycle modified FOLFOXIRI plus CE induction therapy.

**Materials and methods**

**Study design and patient eligibility**

This study was approved by the Medical Ethics Committee from The First Affiliated Hospital, Sun Yat-sen University, and an exemption from informed consent was obtained from our responsible Investigational Ethics Review Board. The clinical and molecular characteristics and outcome data for Asian postmenopausal women with treatment-naive KRAS and BRAF wt mCRC retrieved from a registry database were identified at four medical centers from August 2012 to August 2017. Patient data regarding drug delivery, general condition, and survival status were obtained from medical records.

The cohort consisted of 334 Asian postmenopausal women who had undergone first-line 8-cycle modified FOLFOXIRI plus CE induction therapy followed by CE or BE maintenance. The main inclusion criteria were: age 60 to 76 years; histologically confirmed adenocarcinoma of the colon or rectum; harboring KRAS and BRAF wt mutations, regardless of NRAS; a life expectancy ≥2 years excluding the mCRC diagnosis; at least one measurable lesion assessed in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version v1.1; treatment-naive mCRC according to RECIST version 1.1; adequate hematologic, liver, bone marrow and renal function, as previously described;12,14 and an Eastern Collaborative Oncology Group score of 0 to 1. The main exclusion criteria were: KRAS- and BRAF-mutated mCRC with progression following induction therapy with modified FOLFOXIRI plus CE; a history of chemotherapy for mCRC; without rigid proctoscopy; gastrointestinal perforation; intestinal obstruction; severe circulatory diseases (e.g. clinically significant cardiovascular events within 6 months or cardiovascular events requiring medication); severe organ failure; uncontrolled metabolic dysfunction; discontinuation or interruption of CE or BE regimen; tumor invading major blood vessels; a high risk of bleeding; focal or mental deficits; a New York Heart Association classification of 3; delirium or other cognitive impairment;15 and no or poor pretreatment image data or inadequate medical records. Data were collected by four investigators (one per institution) and were reviewed by a fifth investigator. The co-primary clinical endpoints were PFS and OS; the secondary clinical endpoint was AEs.

**Definitions of the descriptive variables**

The definition of treatment-naive KRAS and BRAF wt mCRC in the present study is in line with a previous report.16 The first occurrence of metastatic disease, which was confirmed by adequate radiological imaging, was considered unresectable. Disease progression or tumor response was assessed using RECIST version v1.1. PFS was defined as the time from the onset of maintenance to the evidence of progression or death from any cause, whichever occurred first; OS was defined as the time from the onset of maintenance to death from any cause. For PFS evaluation, cases were censored at the final follow-up if progression or death did not occur. For OS evaluation, cases were censored at the final follow-up if death did not occur.

Tissue handling was consistent with ESMO consensus guidelines.17 At least 50% tumor content was provided on primary or metastatic samples. The DNeasy kit (Qiagen Inc., Valencia, CA, USA) was used to extract DNA from formalin-fixed, paraffin-
embedded tumor tissue. The time from tissue sampling to fixation was limited to less than 10 minutes to reduce the degradation of proteins and nucleic acids. The fixation time was between 6 and 12 hours. Biomarker analyses (KRAS and BRAF mutations) were performed within 1 month using PCR as previously described.11

Symptoms were assessed every 3 months throughout the follow-up period. Disease assessment by contrast-enhanced computed tomography was performed every 4 weeks until disease progression, withdrawal, unacceptable AEs, or death. Safety assessments (physical examination, AEs, and routine laboratory tests) were performed at least every 2 weeks for the initial 12 weeks of treatment and at least every 4 weeks thereafter. AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

Study design and treatment
A retrospective multi-center study was carried out in which eligible patients received 8-cycle modified FOLFOXIRI plus CE induction therapy every 2 weeks for up to eight cycles, as described by Cremolini et al.,8 followed by CE (intravenous 500 mg/m² over 60 minutes, q2w) or BE (intravenous dose of 5 mg/kg over 30 minutes, q2w) maintenance. Maintenance treatment was continued until disease progression, withdrawal, unacceptable AEs, or death for patients who were stable or better after the completion of initial induction therapy.

Statistical analysis
The statistical methods used in this study have previously been described.14 Briefly, categorical data and continuous data were compared using the chi-square test or Mann–Whitney U-test and Student’s t test, respectively. The reverse Kaplan–Meier method was used to assess the median period of follow-up. Co-primary endpoints (survival curves) were estimated using Kaplan–Meier methods. In the multivariate analyses, hazard ratios (HRs) and appropriate 95% confidence intervals (CIs) were assessed using the logistic regression model and Cox proportional hazard model, respectively. Statistical analyses were performed using SPSS software, version 24.0 (IBM, Inc., Armonk, NY, USA). All P values were two-sided. P values of 0.05 or less were considered statistically significant.

Results
Comparison of baseline data
Between August 2012 and August 2017, 334 postmenopausal women were enrolled in the study. One hundred and twelve patients were deemed ineligible on the basis of exclusion criteria, leaving 222 patients. Of these, 110 received CE (mean age, 68.5 years [SD 7.62]) and 112 received BE (mean age, 68.4 years [SD 6.88]) (Figure 1). Patient characteristics are summarized in Table 1, and similar baseline characteristics were observed between groups regardless of other gene mutations. The median duration of follow-up was 27.0 months (interquartile range, 6.5–38.6 months). There were no significant between-group differences in patient demographics or baseline characteristics. However, disease progression occurred significantly more frequently in the BE group than in the CE group (38.4% vs 25.5%, respectively; P = 0.039) (Table 2). During maintenance treatment, a 25% dropout rate was detected.

Comparison of efficacy
At the final follow-up, the median PFS was 21.9 months (95% CI 16.4–24.4 months) in the CE group and 17.7 months (95% CI 11.3–19.0) in the BE group. The median
From August 2012 to August 2017, 334 Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) were identified and initially received 8-cycle modified FOLFOXIRI plus cetuximab (CE) induction therapy every 2 weeks for up to 8 cycles followed by CE (intravenous 500 mg/m² over 60 minutes, q2w) or BE (intravenous dose of 5 mg/kg over 30 minutes, q2w) maintenance

Discontinuation or interruption of CE or BE regimen (n = 12)
- Tumor invading the major blood vessels (n = 2)
- A high risk of bleeding (n = 2)
- Focal or mental deficits (n = 4)
- New York Heart Association classification of 3 (n = 7)
- Delirious or otherwise cognitively impaired (n = 3)
- No or poor pre-treatment image data or inadequate medical records (n = 14)

Reasons for exclusion (n = 112)
- KRAS- and BRAF-mutated mCRC with progression following induction therapy with modified FOLFOXIRI plus CE (n = 28)
- A history of chemotherapy for mCRC (n = 8)
- Patients without rigid proctoscopy (n = 4)
- Gastrointestinal perforation (n = 3)
- Intestinal obstruction (n = 10)
- Severe circulatory diseases (n = 7)
- Severe organ failure (n = 3)
- Uncontrolled metabolic dysfunction (n = 5)

Eligible for final analysis (n = 222)

Group CE (n=110)  Allocation  Group BE (n=112)

Figure 1. Flow diagram demonstrating methods for the identification of studies to retrospectively assess the efficacy and safety of CE versus BE in maintenance treatment following prior 8-cycle modified FOLFOXIRI plus CE induction therapy in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC).

CE: cetuximab; BE: bevacizumab; FOLFOXIRI, 5-fluorouracil, folinate, oxaliplatin, and irinotecan.

OS was 26.0 months (95% CI 23.4–28.7) in the CE group and 22.7 months (95% CI 21.2–24.3) in the BE group. Significant between-group differences were detected in the median PFS (HR 0.31, 95% CI 0.15–0.46; P < 0.005) (Figure 2) and median OS (HR 0.22, 95% CI 0.11–0.37; P = 0.026) (Figure 3).

Adverse events

Regarding the safety profile, the incidence of main treatment-related AEs is summarized in Table 3. BE appeared to be safer than CE regarding skin toxicity, according to the observed toxicity profile. The frequency and severity of treatment-related AEs were in accordance with the known safety profile. Skin toxicity occurred in 27 patients (12.2%) in both groups, including two (0.9%) with hand-foot syndrome, which occurred during the first 3 months of the CE maintenance phase in 19 patients and during the first 7 months of the BE maintenance phase in eight patients. Hypertension was significantly more frequent in the CE group than in the BE group (21.8% vs 10.7%, respectively; P = 0.025). Dose modifications for AEs were required in some patients, occurring
in 22 cases who had a dose reduction (16 [14.5%] for CE and six [5.4%] for BE; \( P = 0.022 \)) due to grade 3 to 4 neutropenia. Other grade 3/4 AEs included diarrhea (n = 32 [14.4%]), asthenia (n = 25 [11.3%]), and stomatitis (n = 13 cases [5.9%]).

**Table 1.** Patient demographics between groups.

| Variable                        | CE (n = 110) | BE (n = 112) | \( P \)-value |
|---------------------------------|--------------|--------------|---------------|
| Age at onset (years)            | 68.5 ± 7.62  | 68.4 ± 6.88  | 0.217\(^a\)   |
| Primary tumor site              |              |              | 0.650\(^b\)   |
| Right-sided (cecum to transverse colon) | 47           | 46           |               |
| Left-sided (splenic flexure to rectum) | 45           | 44           |               |
| Multiple sites                  | 18           | 22           |               |
| Site of specimen                |              |              | 0.673\(^b\)   |
| Primary tumor                   | 91           | 95           |               |
| Metastatic tumor                | 19           | 17           |               |
| Duration of treatment (months)  | 26.5 ± 13.24 | 26.6 ± 15.27 | 0.143\(^a\)   |
| Performance status (ECOG)       |              |              | 0.764\(^b\)   |
| 0                               | 43           | 46           |               |
| 1                               | 67           | 66           |               |
| Number of metastatic sites      |              |              | 0.623\(^b\)   |
| 1                               | 23           | 21           |               |
| >1                              | 74           | 76           |               |
| Unknown                         | 13           | 15           |               |
| Response to prior induction treatment |              |              | 0.829\(^b\)   |
| Stable disease                  | 58           | 56           |               |
| Partial response                | 21           | 24           |               |
| Complete response               | 19           | 22           |               |
| No change                       | 12           | 10           |               |
| Time from induction treatment to start of maintenance treatment |           |              | 0.465\(^b\)   |
| \( \leq \) 2 weeks              | 97           | 95           |               |
| >2 weeks                        | 13           | 17           |               |

\(^a\) Analyzed using an independent samples t-test; \(^b\) Analyzed using the Mann–Whitney test. CE: cetuximab; BE: bevacizumab; ECOG: Eastern Collaborative Oncology Group.

Discussion

Our study followed Asian postmenopausal women with treatment-naive KRAS and BRAF wt mCRC for a median duration of more than 2 years. Our results confirm the feasibility of CE or BE maintenance following prior 8-cycle modified FOLFOXIRI plus CE induction treatment. The superiority of CE over BE in the setting demonstrates a tendency to be positive.

Our study results, in line with other similar studies,\(^6\,15,16\) provide evidence that CE tends to improve the survival benefit of patients with treatment-naive KRAS and BRAF wt mCRC. In a previous prospective, multi-center randomized Phase 2 trial,\(^6\) 143 enrolled patients with RAS and BRAF wt mCRC were randomized to undergo a first-line induction treatment of modified FOLFOXIRI plus CE followed by CE or BE. In the maintenance population of this study, the median PFS was 13.3 months (95% CI 11.2–17.3 months) for CE and 10.8 months (95% CI 9.3–13.9 months) for BE (HR, 0.73; 95% CI 0.46–1.17), while
the median OS was 37.5 months (95% CI 32.0 to not estimable) for CE and 37.0 months (95% CI 30.0 to not estimable) for BE (HR, 0.98; 95% CI 0.52–1.87). It is unclear why these similar treatment regimens failed to translate into parallel gains in survival benefit. A potential explanation for the worse-than-expected median PFS or median OS performance of the maintenance phase between the trial and our study may be the choice of the research object or that we do not fully understand how the menopausal hormone affects KRAS and BRAF wt mCRC.17–19 In our study, the choice of CE as monotherapy instead of its combination with BE might have affected the survival benefit. Of additional interest is the large effect of CE on mCRC treatment in the first year and its minimal effect thereafter. As expected, not all cases completed the maintenance period and a 25% dropout rate was observed, but this was significantly lower than the previous report of 33%.6 Nevertheless, the importance of converting BE into CE as maintenance was not predetermined at the time of implementing this treatment schedule, mainly because of objective factors (i.e., BE deficiency).

RAS-mutated mCRC, defined by mutations in KRAS and NRAS exons 2 to 4, is associated with a poor PFS and/or OS, reflecting an interaction between RAS-mutated subtypes.6,20,21 Frequent debate has occurred regarding the influence of RAS-mutated subtypes of patients, particularly those with mCRC harboring mutations in KRAS and BRAF.22,23 There is also a paucity of survival data in the published studies about Asian postmenopausal women with treatment-naive KRAS and BRAF wt mCRC. However, survival data reported with CE maintenance tend to be favorable even when compared with other forms of maintenance in cases with fewer previous therapies.6,9,15 Although our study recognizes a distinct separation of PFS or OS curves favoring the continuation of CE maintenance rather than the switch to BE maintenance, our subjects were limited to Asian postmenopausal women. A strong adherence to protocol regimen in treatment following prior 8-cycle modified FOLFOXIRI plus CE was reintroduced in 71.6% of patients with treatment-naive KRAS and BRAF wt mCRC.6 Although the reintroduction of CE or BE used during the maintenance phase is supported by previous trials,6,10,15 the continuation of CE beyond progression failed to provide encouraging outcomes in the CAPRIGOIM trial.24,25 In contrast to prior reports,6,24 however, we detected a non-significant interaction between drug and mutation status; in relation to PFS and OS, there appeared to be trends towards a greater CE benefit compared with BE although this was limited by the population size.

Our study has a number of limitations. First, its retrospective nature reduces the power to draw reliable conclusions, and

| Variable                  | CE (n = 110) | BE (n = 112) | P-value |
|---------------------------|-------------|-------------|---------|
| Disease progression       | 28 (25.5%)  | 43 (38.4%)  | 0.039*  |
| Metastatic brain/leptomeningeal tumors | 22 (20%)   | 25 (22.3%)  | 0.672a  |
| >3 metastases# | 26 (23.6%)  | 31 (27.7%)  | 0.491a  |

*Statistically significant values. aAnalyzed using the chi-square test. #involving the brain, bone, lung, and liver. CE: cetuximab; BE: bevacizumab; wt: wild-type; mCRC: metastatic colorectal cancer.
all potential confounding variables (i.e., underlying diseases) may not have been addressed in the study. Second, the small number of patients may have introduced bias, preventing us from drawing preferred conclusions about the maintenance approach. Third, our analysis lacks generalizability because the study population only included Asian postmenopausal women with treatment-naive KRAS and BRAF wt mCRC. Finally, the power tended to be underestimated, mainly because of repeated observations of each subject.

In conclusion, the results reported here stimulate a growing body of evidence that CE maintenance following prior 8-cycle modified FOLFOXIRI plus CE induction therapy in Asian postmenopausal women with treatment-naive KRAS and BRAF wt mCRC tends to be more poorly tolerated but has a slightly more modest, if any, survival benefit compared with BE maintenance. In light of our findings, we are not

Figure 2. Kaplan–Meier curves for progression-free survival. The median progression-free survival (PFS) time was 21.9 months (95% confidence interval [CI] 16.4–24.4) and 17.7 months (95% CI 11.3–19.0) for the CE and BE groups, respectively. A significant difference was observed in PFS between groups. The hazard ratio was calculated using a Cox proportional-hazards model, with the type of age, site of primary tumor, number of metastatic sites, and performance status as covariates and CE/BE therapy as the time-dependent factor. Regarding PFS, the log-rank test gave a P < 0.005. CE: cetuximab; BE: bevacizumab.
The median overall survival (OS) time was 26.0 months (95% CI 23.4–28.7) and 22.7 months (95% CI 21.2–24.3) for the CE and BE groups, respectively. A significant difference was detected in OS between groups. *The hazard ratio was calculated using a Cox proportional-hazards model, with the type of age, site of primary tumor, number of metastatic sites, and performance status as covariates and CE/BE therapy as the time-dependent factor. Regarding OS, the log-rank test gave a $P = 0.026$.

CE: cetuximab; BE: bevacizumab.

**Table 3.** Comparison of the incidence of major treatment-related grade 3 or 4 AEs between groups at the final follow-up.

| AEs            | CE (n = 110) | BE (n = 112) | $P$-value |
|----------------|--------------|--------------|-----------|
| Skin toxicity  | 19 (17.3%)   | 8 (7.1%)     | 0.021*    |
| Hypertension   | 24 (21.8%)   | 12 (10.7%)   | 0.025*    |
| Neutropenia    | 16 (14.5%)   | 6 (5.4%)     | 0.022*    |
| Diarrhea       | 17 (15.5%)   | 15 (13.4%)   | 0.662*    |
| Asthenia       | 11 (10.0%)   | 14 (12.5%)   | 0.556*    |
| Stomatitis     | 5 (4.5%)     | 8 (7.1%)     | 0.410*    |

*Statistically significant values. Analyzed using the Chi-square test. AEs: adverse events; CE: cetuximab; BE: bevacizumab.
currently advocating the use of BE maintenance as a clinical decision in Asian post-menopausal women with treatment-naive KRAS and BRAF wt mCRC. Further evidence-based prospective assessment of the long-term efficacy and safety of CE or BE in a similar setting should be performed to confirm our findings.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iDs
Weiguang Yu https://orcid.org/0000-0001-6190-8336
Guowei Han https://orcid.org/0000-0003-3442-2415

References
1. Normanno N, Rachiglio AM, Lambiase M, et al. Heterogeneity of KRAS, NRAS, Braf and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol 2015; 26: 1710–1714.
2. Salvatore L, Loupakis F, Cremolini C, et al. KRAS and BRAF mutational analyses in a Phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (PTS). EJC Suppl 2009; 7: 339.
3. Pfeiffer P, Kohne CH and Qvortrup C. The changing face of treatment for metastatic colorectal cancer. Expert Rev Anticancer Ther 2019; 19: 61–70.
4. Rahman A. FOLFOXIRI and bevacizumab in metastatic colorectal cancer. Lancet Oncol 2014; 15: E590.
5. Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomized phase II trial. Ann Oncol 2015; 26: 702–708.
6. Cremolini C, Antoniotti C, Lonardi S, et al. Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer a randomized Phase 2 clinical trial. JAMA Oncol 2018; 4: 529–536.
7. Oki E, Kato T, Bando H, et al. A multicenter clinical Phase II study of FOLFOXIRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO study. Clin Colorectal Cancer 2018; 17: 147–155.
8. Ledin E, Mochalova A and Zaitseva Y. The clinical effectiveness and safety of re-induction oxaliplatin, irinotecan and fluorouracil (FOLFOXIRI regimen) for the treatment of metastatic colorectal cancer after two lines of chemotherapy (oxaliplatin-and irinotecan-based regimens). Ann Oncol 2018; 29: v77.
9. Fornaro L, Lonardi S, Masi G, et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2013; 24: 2062–2067.
10. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306–1315.
11. Cremolini C, Loupakis F, Masi G, et al. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Ann Oncol 2016; 27: 843–849.
12. Folprecht G, Hamann S, Schutte K, et al. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line
therapy of patients with metastatic colorectal cancer. *BMC Cancer* 2014; 14: 521.

13. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *N Engl J Med* 2014; 371: 1609–1618.

14. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016; 27: 1386–1422.

15. Cremolini C, Antoniotti C, Lonardi S, et al. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. *Ann Oncol* 2018; 29: 1528–1534.

16. Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. *Lancet Oncol* 2010; 11: 845–852.

17. Tsilidis KK, Allen NE, Key TJ, et al. Menopausal hormone therapy and risk of colorectal cancer in the European prospective investigation into cancer and nutrition. *Int J Cancer* 2011; 128: 1881–1889.

18. Morois S, Fournier A, Clavel-Chapelon F, et al. Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: true associations or bias? *Eur J Epidemiol* 2012; 27: 439–452.

19. Rudolph A, Sainz J, Hein R, et al. Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes. *Endocr Relat Cancer* 2011; 18: 371–384.

20. Cremolini C, Antoniotti C, Loupakis F, et al. Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): the phase II randomized MACBETH trial by GONO. *Ann Oncol* 2016; 27: iv1.

21. Deng YH, Hu HB, Liu GJ, et al. FOLFOXIRI with or without bevacizumab as first-line treatment for unresectable liver-only metastatic colorectal cancer patients with RAS mutation-type. *J Clin Oncol* 2015; 33 Suppl: Abstr TPS2364.

22. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. *Br J Cancer* 2009; 101: 715–721.

23. Antoniotti C, Cremolini C, Loupakis F, et al. Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO. *Ann Oncol* 2016; 27: 121–122.

24. Ciardiello F, Normanno N, Maiello E, et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. *Ann Oncol* 2014; 25: 1756–1761.

25. Martinelli E, Cardone C, Troiani T, et al. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. *ESMO Open* 2016; 1: e000086.